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We confirmed the knockout of ADAM17 in isolated endothelial cells, which has already been reported for this mice strain (1) , by differential CD45-and CD31-sorting of digested lung cells. The CD31 + -fraction showed a 50% reduction of ADAM17 mRNA expression in Tie2-
adam17
-/-mice, whereas no differences to control mice were observed for the CD45 + -fraction (supplemental figure 5A,B) . Additionally, we showed that the blood of control and Tie2-adam17 -/-mice (both without inflammatory stimulus) did not differ with respect to the total leukocyte, neutrophil, or monocyte counts (supplemental figure 5C-E) nor in their ADAM17 mRNA expression level in these cells (supplemental figure 5F,G). Moreover, the ADAM17-dependent TNFα-release upon LPS stimulation of primary alveolar macrophages did not differ between control and Tie2-adam17 -/-mice (data not shown). Thus, Tie2-adam17 -/-mice showed the expected knockout of ADAM17 in endothelial cells and had normal numbers of peripheral blood leukocytes with normal ADAM17 mRNA expression and normal capacity of TNFα-release by alveolar macrophages.
Materials and Methods

Antibodies, cytokines and inhibitors
Mouse monoclonal antibodies against human ADAM10 and ADAM17, respectively, mouse
IgG2b and IgG1 isotype controls were from R&D System (Wiesbaden, Germany). The APCconjugated and the HRP-conjugated goat anti-mouse secondary antibodies were from Jackson
ImmunoResearch Laboratories, Inc (West Grove, USA). The Alexa555-conjugated goat antirabbit secondary antibody was from Invitrogen (Frankfurt, Germany). Rat monoclonal antibody against murine CD31 (PECAM) (PE-labeled and unlabeled) was from BD Pharmingen (Heidelberg, Germany) and anti-rat magnetic microbeads from Miltenyi (Bergisch Gladbach, Germany). The rat allophycocyanin (APC)-labeled monoclonal antibody against murine Ly6G (APC-anti-mLy6G) and the rat monoclonal VioBlue-labeled antimCD45R were from Miltenyi. Rat monoclonal antibodies APC-labeled anti-mCD4 and
PacificBlue-labeled anti-mCD8a were from BD Pharmingen. Fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled rat monoclonal antibody against murine F4/80 was from AbD Serotec (Düsseldorf, Germany). Cy5-conjugated PE-labeled (PeCy5) armenian hamster monoclonal antibody against murine CD3e was from eBiosciences (NatuTec, Frankfurt, Germany). Cy TM 7-conjugated PE-labeled (PE-Cy TM 7) monoclonal rat antibodies against murine NK1.1, CD4, and CD11b were from BD Pharmingen. Cy TM 5-conjugated PElabeled antibodies against murine CD8 and CD19 were obtained from BD Pharmingen.
CD16/32 Fc-Block was obtained from eBiosciences. Rabbit polyclonal antibody against β-catenin was from Santa Cruz Biotechnology, Inc (Delaware, USA). The mouse monoclonal antibody against human JAM-A was from BD Pharmingen. Lipopolysaccharide (LPS) from E. coli 0127:B8 was from Sigma-Aldrich (Munich, Germany), human and murine TNFα and IFNγ were from R&D Systems. Human LBP was from Peprotech (Rocky Hill, USA). The metalloproteinase inhibitor GW280264 was synthesized and assayed for inhibition of human and mouse ADAM17 and ADAM10 as described (2) . The Complete Protease Inhibitor was from Roche (Munich, Germany).
Primary cells and cell culture
Lung human microvascular endothelial cells (HMVEC-L) (Lonza, Belgium) were cultured in EGM-2 MV medium (Lonza) and subcultured following the manufacturer's protocol. Cells were used in passage 4 for viral transduction and passage 5 to 6 for all assays. Before stimulation with 1 µg/ml LPS, non-adherent cells were removed, and after 4 hours the TNFα release to the cell culture supernatant was measured by ELISA.
Immunohistochemistry
HMVEC-L were grown on 48-well tissue culture plates to complete monolayers. Cells were washed with PBS and fixed for 15 min in 4% PFA, followed by 10 min incubation with 50 mM NH 4 Cl and permeabilization in 1% Triton X-100 in PBS for 4 min. After washing, cells were blocked in PBS/5% FBS for 30 min, followed by incubation with rat anti-m-β-catenin antibody for 30 min (6) . Cells were washed, incubated with Alexa555-coupled anti-rat antibody for 30 min, DAPI-stained and at least covered with Immu-Mount (ThermoScientific, USA). Fluorescence microscopy was performed using the Leica DMI14000B (Leica Microsystems, Germany) with an image analysis package (DISKUS, Technisches Büro Carl H. Hilgers, Königswinter, Germany).
RT-qPCR analysis
The mRNA levels of ADAM10 and ADAM17 in murine lung tissue and BAL fluid cells as well as the mRNA levels of ADAM9, 10, 15, and 17, and MMP7 in HMVEC-L were quantified by RT-qPCR analysis and normalized to the mRNA level of murine RPS29 or human GAPDH. RNA was extracted using RNeasy Kit (Qiagen, Hilden, Germany) and quantified by spectrophotometry (NanoDrop, Peqlab, Germany). RNA (equal amounts within each data set) was reverse transcribed using RevertAid First Strand cDNA Synthesis Kit 
Transmigration assay
Neutrophils were isolated as described before (4) . HMVEC-L were seeded on collagen-coated polycarbonate transwell filters with 5 µm-pores (Costar, Lowell, USA) and grown to confluence. 24-well culture plates were filled with 600 µl/well DMEM containing 0.2% BSA with or without 10 ng/ml IL-8 (R&D Systems). The transwells were transferred into the wells and filled with 100 µl of neutrophil suspension (2x10 5 neutrophils per well). After incubation for 30 min at 37°C and 5% CO 2 , transwells were carefully removed and transmigrated cells were quantified by measurement of endogenous glucuronidase activity as describe before (7).
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For inhibition of ADAM10 and ADAM17, GW280264 (10 µM) was added to HMVEC-L layers 1.5 h prior to the assay.
Permeability assay
HMVEC-L were seeded on collagen-coated polycarbonate transwell filters with 5 µm-pores (Costar) and grown to confluence. For lentivirally-transduced HMVEC-L expressing green fluorescent protein (GFP), confluence was controlled by fluorescence microscopy. After 24 h stimulation with LPS (1 µg/ml) or/and GW280264 (10 µM), the cell culture medium in the upper chamber was replaced by 70 kDa TRITC-dextran suspension (Sigma-Aldrich, 1 mg/ml in PBS with 0.2% BSA,). After 90 min incubation at 37°C and 5% CO 2 , permeability was analyzed by measurement of the fluorescence intensity in the lower chamber at 535 nm excitation and 595 nM emission wavelength using XFluor4 Genios (Tecan, Grödig, Austria).
JAM-A cleavage assay
HMVEC-L were seeded on 6-wells and grown to confluence. JAM-A release to cell culture supernatant was performed as previously described (8) .
LPS and TNF model of acute lung inflammtion
Mice were anesthesized by intraperitoneal injection of ketamin (100 mg/kg) und xylazin ( Values were standardized on equal volumes of BAL recovery.
Determination of protein content
The protein content of BAL fluid, tissue lysates and cell lysates (each in equal volumes of recovery) was determined using a commercial BC assay kit (Interchim) following the manufacturer's protocol. Linearity was determined using a bovine serum albumin (0 to 3000 ng/ml) standard in the aquivalent probe solution.
Flow cytometry
PBS supplemented with 1% FCS and 5 mM EDTA (sterile filtered) was used as assay buffer, and all steps of the staining process were performed at 4°C. L-HMVEC cells were detached from culture dishes using accutase (PAA, Cölbe, Germany) and analyzed for expression of ADAM10 and ADAM17 by incubation with mouse monoclonal antibodies against ADAM10
and ADAM17 (1 µg/ml and 5 µg/ml resp.) followed by incubation with a APC-conjugated 
